Short Interest in Pulmatrix, Inc. (NASDAQ:PULM) Declines By 25.1%

Pulmatrix, Inc. (NASDAQ:PULM) saw a large decline in short interest in December. As of December 15th, there was short interest totaling 4,299 shares, a decline of 25.1% from the November 30th total of 5,742 shares. Based on an average daily trading volume, of 13,084 shares, the days-to-cover ratio is currently 0.3 days. Currently, 0.1% of the shares of the stock are sold short. Currently, 0.1% of the shares of the stock are sold short. Based on an average daily trading volume, of 13,084 shares, the days-to-cover ratio is currently 0.3 days.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Pulmatrix stock. SBI Securities Co. Ltd. grew its position in Pulmatrix, Inc. (NASDAQ:PULM) by 15.7% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 60,565 shares of the biotechnology company’s stock after acquiring an additional 8,208 shares during the quarter. SBI Securities Co. Ltd.’s holdings in Pulmatrix were worth $418,000 at the end of the most recent reporting period. 11.84% of the stock is owned by hedge funds and other institutional investors.

Pulmatrix Price Performance

Shares of NASDAQ PULM traded down $0.04 during mid-day trading on Tuesday, hitting $2.18. 35,603 shares of the company’s stock traded hands, compared to its average volume of 23,420. Pulmatrix has a 1 year low of $2.15 and a 1 year high of $10.40. The company’s 50-day moving average is $4.27 and its two-hundred day moving average is $5.09. The company has a market capitalization of $7.96 million, a P/E ratio of -1.28 and a beta of 1.58.

Pulmatrix (NASDAQ:PULM) last issued its quarterly earnings data on Thursday, October 16th. The biotechnology company reported ($0.24) earnings per share for the quarter.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Pulmatrix in a research report on Monday. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Pulmatrix currently has a consensus rating of “Sell”.

Pulmatrix Company Profile

Pulmatrix, Inc is a clinical-stage biopharmaceutical company dedicated to developing inhaled therapies for patients suffering from respiratory diseases. The company’s proprietary iSPERSE® dry-powder formulation platform produces fine microparticles optimized for deep-lung delivery, rapid absorption and consistent dosing, addressing challenges often encountered with traditional inhalation approaches.

Among Pulmatrix’s lead programs is PUR1900, an inhaled therapy designed to treat pulmonary fungal infections such as allergic bronchopulmonary aspergillosis (ABPA).